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Summary
Nonalcoholic fatty liver disease (NAFLD) has become in-
creasingly recognized as a public health problem around 
the word, which has become endemic in the industrialized 
countries. The etiology of NAFLD remains unknown, but 
specialists have established a strong association with 
age, gender, body mass index (BMI), body iron status and 
individual components of the metabolic syndrome (MS) 
such as type 2 diabetes, hypertension and hyperlipidemia. 
There is evidence supporting the view that hemoglobin may 
serve as a marker for injuries and diseases associated with 
glycemia, oxidative stress, hypertension, insulin resistance, 
obesity, and diabetes. Body iron levels play a critical role 
in NAFLD and the MS. Elevated hemoglobin levels may 
cause increased blood viscosity and decreased blood fl ow 
to the liver leading to hypoxia-related liver damages. The 
multivariate analysis showed that hemoglobin level is a 
good predictor for individuals with suspected NAFLD with 
or without the MS. Infl ammation could lead to anisocytosis 
via release of immature red blood cells into the peripheral 
circulation. Increased red blood cell distribution width 
(RDW) in patients with hepatosteatosis compared to healthy 
controls is not surprising, because hepatosteatosis is associ-
ated with a subclinical infl ammation. Body iron levels are 
important risk factor for NAFLD and incorporation of body 
iron levels as a predictor may help to prevent liver damages 
in patients with NAFLD. The dysmetabolic iron overload 
syndrome (DIOS) is detected in about one third of patients 
with NAFLD and the MS. All of these settings suggest that 
hemoglobin test should be considered as a part of clinical 
evaluation for patients with NAFLD. 
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Влияние высокого уровня гемоглобина на риск 
развития безалкогольной жировой дистрофии 
печени
Безалкогольная жировая дистрофия печени является 
признанной проблемой мирового здравоохранения 
и особенно актуальна для промышленно развитых 
стран. Этиология этого заболевания остается 
неизвестной, но была установлена прочная ассоциация 
с возрастом, полом, индексом массы тела, уровнем 
железа в организме и отдельными компонентами 
метаболического синдрома, такими как сахарный 
диабет 2 типа, гипертония и гиперлипидемия. Есть 
доказательства, поддерживающие представление, что 
гемоглобин может служить маркером повреждения и 
патологий, связанных с гипергликемией, оксидативным 
стрессом, гипертонией, резистентностью к инсулину, 
ожирением и диабетом. Уровень железа в организме 
играет решающую роль в патогенезе безалкогольной 
жировой дистрофии печени и метаболического 
синдрома. Высокий уровень гемоглобина может 
вызывать увеличение вязкости крови, уменьшая тем 
самым кровоток, приводящий к связанным с гипоксией 
повреждениям печени. Мультивариантный анализ 
показал, что уровень гемоглобина – хороший предиктор 
безалкогольной жировой дистрофии. Воспаление 
может провоцировать анизоцитоз, вызванный 
появлением незрелых эритроцитов в периферической 
крови. Увеличение распределения эритроцитов 
по объему у пациентов со стеатогепатитом не 
удивительно, потому что при этой патологии 
имеется воспаление. Уровень железа в организме 
– важный  фактор  риска  для  безалкогольной
жировой дистрофии печени и оценка состояния 
метаболизма железа, как предиктора, может помочь 
предотвратить повреждение печени у пациентов 
с этой патологией. Синдром дисметаболического 
избытка железа обнаружен приблизительно у одной 
трети пациентов безалкогольной жировой дистрофии 
печени и метаболическим синдромом. Все эти данные 
позволяют использовать гемоглобин как параметр 
клинической оценки пациентов с безалкогольной 
жировой дистрофией печени.
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дисметаболического избытка железа 
Introduction
Nonalcoholic fatty liver disease (NAFLD) has 
become increasingly recognized as a public health 
problem around the word, which become endemic 
in the industrialized countries. Several factors com-
mon to the Western lifestyle, such as sedentary be-
havior, diets rich in saturated fats, and central obesity 
are shared risk factors for NAFLD. 
NAFLD is defined as fat accumulation in the 
liver exceeding 5% to 10% by weight in the absence 
of alcohol abuse (less than 140 ml of alcohol per 
week). NAFLD symptoms range from simple steatosis 
to nonalcoholic steatohepatitis (NASH), and to ad-
vanced fibrosis and cirrhosis. The etiology of NAFLD 
remains unknown, but specialist have established 
a strong association with age, gender, body mass 
index (BMI), body iron status and individual compo-
nents of the metabolic syndrome (MS) such as type 
2 diabetes, hypertension and hyperlipidemia.
Iron is an essential element for the growth and 
well-being of almost all living organisms. It is an ac-
cess to a wide range of redox potentials and can par-
ticipate in many electron transfer reactions, spanning 
the standard redox potential range. It is also involved 
in O2 transport, activation, and detoxification. Trace 
metals play an important catalytic role with lipids in 
the formation of reactive oxygen species and oxida-
tive stress. Iron, in particular, is a key component in 
catalyzing the production of reactive radicals and 
creating lipid peroxidation and oxidative stress.
There is the evidence supporting the view 
that hemoglobin may serve as a marker for injuries 
and diseases associated with glycemia, oxidative 
stress, hypertension, insulin resistance, obesity, and 
diabetes. 
The liver is a major site for the storage of iron 
and the metabolism of lipids and is therefore an 
important site for interaction between these two 
metabolic pathways. 
The present study explored and summarized 
the evidence and relationships between hemoglobin 
level and risk of NAFLD. 
Effect of iron on lipids metabolism: iron overload 
and lipid peroxidation 
Iron (Fe) is an essential element for all living 
cells. Most of iron within the body is found in hemo-
globin within erythrocytes, contributing to about 
50% of the body iron. Heme iron is recycled by 
macrophages following degradation of senescent 
red blood cells.
However, Fe tendency to catalyze free-radical 
formation makes free iron potentially cytotoxic. Iron 
is a potent catalyst of oxidative stress via the Fenton 
reaction and can directly cause lipid peroxidation 
generating malonyldialdehyde, which is capable to 
activate hepatic stellate cells (HSCs), a major player 
of fibrogenesis in NAFLD. Iron can also directly in-
duce fibrogenesis, as HSCs can be activated by the 
generation of reactive oxygen species (ROS) with 
ascorbate/FeSO4. Reactive oxygen species (ROS) 
cause peroxidation of polyunsaturated fatty acids 
and nucleic acids.
Furthermore, the amount of iron in cells is 
far above the solubility, and it is necessary to con-
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centrate the excessive iron and to keep it soluble. 
Storage of excessive cytoplasmic iron in soluble and 
nontoxic form is performed in many cell types by 
ferritin. Another potential source of cellular iron is 
extracellular ferritin, whose uptake by early erythroid 
cells is regulated and whose iron can be used for 
heme synthesis. 
The amount of serum ferritin normally reflects 
the amount of iron stored in the body in healthy 
individuals, which is about 20-30% of the body iron. 
However, ferritin is also an acute-phase reactant and 
elevated serum ferritin levels have been associated 
with the severity of liver damage in NAFLD subjects. 
Therefore, under conditions of chronic illness, ferritin 
levels do not reflect the amount of iron stored in the 
body. Unlike serum ferritin, hemoglobin level is less 
affected by the presence of acute inflammation. 
Free radicals and oxidants are continuously 
generated within mammalian cells but are normally 
neutralized by the body’s antioxidant metabolism. 
Oxidative stress can damage lipids, proteins, and 
DNA. Lipid peroxidation is a common product of 
iron-induced oxidation and may be expected to 
occur at the highest rate when both cofactors are 
readily available. Mainous A. et al. support the hypo-
thesis that iron-mediated oxidation of cholesterol 
increases oxidative stress [1]. 
Choi J.W. et al. suggested that iron is directly 
involved in the lipid metabolism, and low density 
lipoprotein (LDL) oxidation process may require 
iron. Girls with severe iron deficiency anemia had 
lower total serum cholesterol and triglycerides 
(TG) concentrations, and that these reduced serum 
lipid levels returned to normal levels following iron 
supplementation [2]. Recently, it has been shown 
that LDL is oxidized by iron within the lysosomes of 
macrophages.
Fe overload in mammals has been often associ-
ated with injury, fibrosis, and cirrhosis in the liver fol-
lowed by cardiac disease, endocrine abnormalities, 
arthropathy, osteoporosis and skin pigmentation. 
Thus, alterations in Fe metabolism should be ca-
refully analyzed before evaluating cellular responses 
to either damaging agents or xenobiotics of biome-
dical or ecological impact since Fe is a double-faced 
element that can be either good or bad to the cell, 
depending on whether it serves as a micronutrient 
or as a catalyst of free radical reactions. 
Effect of lipids on heme synthesis and iron me-
tabolism 
The liver is an important organ for iron and lipid 
metabolism. Deregulation of fat metabolism in the 
fatty liver is associated with overproduction of low 
density lipoprotein (LDL), very low density lipopro-
tein (VLDL) and triglycerides. LDL oxidation plays a 
pivotal role in the development of atherosclerosis.
Phospholipids were divided into three groups 
in dependence of effect on heme synthesis. The first 
is the choline-containing group (lecithin and sphin-
gomyelin) with inhibitory or slightly accelerating 
action on heme synthesis. The second group is the 
acid phospholipids namely phosphatidylethanola-
mine, cardiolipin, phosphatidic acid and phosphati-
dylenositol, were strong activators and the intensity 
of activation was in the order of the acidity of the 
phospholipids. The third group contains the lysop-
hospholipids, namely lysolecithin, lysophosphatidy-
lethanolamine and sphingosylphosphorylcholine, 
activated the heme sintesis most effectively. 
An activation mechanism of phospholipids 
was proposed in which the hydrophilic anionic part 
of lipid in the lipoprotein enzyme molecule attract 
ferrous iron. After being removed from solvation wa-
ter, the ferrous iron is transferred to the hydrophobic 
part of the enzyme molecule to be inserted into por-
phyrin. Yoneyama et al. [3] reported that more acidic 
phospholipids including phosphatidylethanolamine, 
are strong activators of the mitochondria enzyme 
protohemeferrolyase which transfers ferrous iron to 
protophorphyrin forming heme. 
In addition, the synthesis of heme may be 
enhanced by the presence of the acidic phospho-
noethanolamine. The resistance of this compound 
to some types of phospholipase hydrolysis, the 
presence of the unique fatty acid and the general 
physical properties of the phosphonoethanolami-
ne contribute to the membrane properties of the 
cellular and subcellular membranes. Alterations 
in membrane permeability may also contribute to 
glyconeogenic activity of the cells. Shug et al. (4) 
suggested that the increased heme synthesis might 
be related to increased glyconeogenesis. 
Green and Fleischer et al. [5] show the relati-
onship of phospholipids participation on the mi-
tochondria respiratory chain (phospholipid plays 
an important role in electron transport, oxidative 
phosphorylation and the energy-linked transport of 
ions across mitochondria membranes). Bertoli et al. 
[6] reported that a pattern exists between respira-
tory activity and cellular phospholipid content. This 
correlation may be due to the role of phospholipids 
in synthesis of heme. In 1971, Peng YM and Elson E 
observed increased synthesis of phospholipids in 
Tetrahymena pyriformis grown in medium supple-
mented with iron [7].
Iron in fatty liver and in the metabolic syndrome 
Body iron levels play a critical role in NAFLD and 
the MS. Serum hemoglobin α and β subunits have 
been identified as biomarkers for biopsy-proven 
NAFLD in adults. A proteomic study has shown that 
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free hemoglobin (Hb) α and β subunits in serum 
were significantly increased from normal controls to 
steatosis and to NASH, suggesting free Hb subunits 
in serum could be a biomarker for liver lesions.
Hemoglobin level as a predictor closely asso-
ciated with NAFLD
Yilmaz et al. show that hemoglobin is the only 
predictor closely associated with NASH and fibrosis 
for the NAFLD patients without the MS. Elevated he-
moglobin levels may cause increased blood viscosity 
and decreased blood flow to the liver leading to 
hypoxia-related liver damages [8]. Yu et al. followed-
up 6,944 initially NAFLD-free Chinese subjects for 3 
years and found hemoglobin to be a strong predic-
tor for NAFLD [9]. A 5-year follow up study on 5,562 
lean Chinese adults who were initially free of NAFLD 
found that hemoglobin and platelet counts were 
significantly associated with the development of 
NAFLD [10]. Bai et al. reported that distribution of 
hemoglobin levels by decade of age showed strong 
correlation with the prevalence of suspected NAFLD 
using gender-specific cut-points. The multivariate 
analysis showed that hemoglobin level is a good 
predictor for individuals with suspected NAFLD 
with or without the MS. In conclusion, adults with 
high hemoglobin levels of 14.4 μg/dl for males and 
13.2 μg/dl for females are at the greatest risk for de-
veloping abnormal liver function. Hemoglobin test 
should be considered as a part of clinical evaluation 
for patients with NAFLD [11].
The major finding of Takemi Akahane study is 
that a high Hb level is an independent predictor of 
NAFLD in Japanese women. The authors found that 
Hb level was higher in subjects with NAFLD than 
in those without. The multivariate analysis showed 
that Hb level correlated with both ferritin level and 
insulin resistance assessed by HOMA, indicating a 
high probability that Hb level is associated with iron 
stores and insulin resistance [12].
In another population study, a higher free se-
rum Hb has been associated with a higher prevalence 
rates of NAFLD. The source of free Hb in serum was 
not identified, but probably it results from oxidative 
stress-induced hemolysis. On the other hand, Liu et 
al. [13] reported that Hb was expressed in hepato-
cytes and it was increased in NASH. They suggested 
that elevated oxidative stress in NASH could induce 
Hb expression and suppression of oxidative stress 
by Hb could be a mechanism to protect hepatocytes 
from oxidative damage.
Red cell distribution width in hepatosteatosis
Red blood cell distribution width (RDW), an 
automated measure of the variation of red blood 
cell sizes (i.e. anisocytosis), is routinely performed as 
a part of a standard complete blood count.
Several studies have reported that RDW was as-
sociated with adverse prognosis in patients with vari-
ous conditions, including diagnosed cardiovascular 
diseases, cancer, chronic lower respiratory diseases, 
stroke and celiac disease [14-17]. 
Kim et al. have attempted to present the associa-
tion of RDW with the degree of fibrosis in NAFLD [18]. 
In their retrospective cross-sectional analysis, study 
subjects with NAFLD were selected based on abdom-
inal ultrasonography and history of alcohol intake 
from a large cohort of individuals who presented 
for a routine health check-up. The degree of fibrosis 
was determined according to the noninvasive fibro-
sis scoring systems including the BARD score and 
the FIB-4 score, and the relationship between RDW 
and the degree of fibrosis was determined. Their 
results revealed a stepwise-increase in RDW with 
increasing level of liver fibrosis. They concluded that 
higher RDW was associated with advanced fibrosis 
in NAFLD patients. The main limitation of this study 
was absent of liver biopsy. Biopsy-based prospective 
longitudinal studies should be aimed at validating 
the diagnostic performance of RDW. 
Some authors suggest that RDW should be an 
inflammatory marker in certain conditions [19, 20]. 
RDW has been found to be associated with disease 
activity in inflammatory bowel disease, another 
inflammatory disease. Chronic inflammation and 
oxidative stress leads to an elevation in RDW. Proin-
flammatory cytokines have been shown to inhibit 
erythropoietin-induced erythrocyte maturation. 
Thus, inflammation could lead to anisocytosis via 
release of immature red blood cells into the periph-
eral circulation. Oxidative stress increases the fragility 
of red blood cells, decreases the rate of erythroid 
maturation and erythrocyte lifespan. 
Gülali Aktaş et al. suggest that increased RDW in 
patients with hepatosteatosis compared to healthy 
controls is not surprising, because hepatosteatosis 
is associated with a subclinic inflammation [21]. This 
study are indicating increased RDW in patients with 
hepatosteatosis compared to controls even both 
groups had similar Hb levels. Likewise, the associa-
tion with chronic inflammation and oxidative stress 
are believed to be proximate mediating mechanisms 
of more advanced fibrosis in NAFLD. 
“Metabolic” hyperferritinemia associated 
with NAFLD
Patients with NAFLD often have a high serum 
ferritin level. Zelber-Sagi et al. [22] demonstrated that 
NAFLD is a major determinant of increased serum 
ferritin level and the association between serum 
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ferritin and insulin levels is much more evident in 
patients with NAFLD than in those without. Many 
studies have suggested that serum ferritin level is a 
marker for insulin resistance [23-25]. Furthermore, 
increased serum ferritin levels have been reported 
as an independent predictor of liver damage (severe 
hepatic fibrosis/ NASH) in patients with biopsy-
proven NAFLD. A specific receptor for ferritin has 
been demonstrated on activated HSCs, and it has 
been proposed that ferritin acts as a cytokine with 
pro-inflammatory activity regulating fibrogenesis via 
nuclear factor kappa B (NFjB) -regulated signaling in 
HSCs. Probably, co-existing liver injury or nutritional/
genetic factors, and in particular the coexistence of 
steatosis, may compromise the ability to mount an 
effective antioxidant defense, and thus predispose 
to fibrogenesis.
Serum level of Fe and Iron overload
Body iron levels are important risk factor for 
NAFLD and incorporation of body iron levels as 
a predictor may help to prevent liver damages in 
patients with NAFLD.
Mild hepatic iron overload is frequently ob-
served in NASH and advanced fibrosis and cirrhosis. 
However, the role of hepatic iron in the progression 
of NASH remains controversial. While some studies 
found that 20% to 62% of individuals with fatty liver 
disease had evidence of iron overload, other stud-
ies failed to show such a relationship. There are two 
factors, with associated mechanisms, to explain the 
increased hepatic iron overload: (1) transferrin recep-
tor 1 (TfR1), which takes up iron bound to transfer-
rin; and (2) hepcidin, which controls intestinal iron 
absorption and regulates the cellular iron export 
protein ferroportin-1 (Fpn1). 
The frequent association between hepatic 
steatosis and body iron overload is known as insulin 
resistance-associated hepatic iron overload. Insulin 
stimulates ferritin synthesis and facilitates iron up-
take, and conversely, iron influences insulin signal-
ing, reduces hepatic extraction and metabolism of 
insulin, which leads to peripheral hyperinsulinemia, 
and may increase cellular oxidative stress, which 
inhibits the internalization and actions of insulin.
Hepatic genes involved in iron metabolism
Mitsuyoshi et al. studied hepatic genes involved 
in iron metabolism in patients with NAFLD and 
reported hepatic iron score increased as the stage 
progressed. The stage progression is associated 
with increased TfR1 genes and decreased hepcidin 
gene expression [26]. Decreased hepatic Fpn1 levels 
and increased serum hepcidin levels were seen in 
patients with biopsy proven NAFLD.
The dysmetabolic iron overload syndrome 
The dysmetabolic iron overload syndrome 
(DIOS) is detected in about one third of patients with 
NAFLD and the MS.  DIOS patients have mild hepatic 
iron excess with a predominantly mixed sinusoidal 
pattern, with macrophage iron retention and an 
iron recycling defect, which influence the natural 
history of liver disease by inducing oxidative stress 
in hepatocytes and activation of hepatic stellate cells. 
Nemeth E. et al. have been reported that in DIOS iron 
absorption is decreased and hepcidin (the hormone 
that decreased intestinal iron absorption and recy-
cling from macrophages [27]) is increased compared 
to healthy controls. Excessive body iron plays a causal 
role in insulin resistance through mechanisms that 
probably reduce theability to burn carbohydrates. 
DIOS may facilitate the progression of cardiovascular 
disease by contributing to the recruitment and acti-
vation of macrophages within arterial lesions.
Definition of DIOS has been based on the 
presence of two or more MS components, steato-
sis, normal transferrin saturation, and mild hepatic 
iron overload, with typical involvement of the sinu-
soidal compartment. The pathogenesis is related 
to altered regulation of iron transport associated 
with steatosis, insulin resistance, and subclinical 
inflammation, often in the presence of predisposing 
genetic factors. 
In conclusion, the growing prevalence of 
obesity and metabolic syndrome, diabetes mellitus 
and dyslipidemia in the society provokes the rising 
prevalence of NAFLD. Iron overload secondary asso-
ciated with NAFLD may be one of the pieces of the 
complicated puzzle that will help understand the 
pathogenesis and treatment of the disease.
The recent description of new condition associ-
ated with liver iron overload, that seem to be related 
with NAFLD, open new perspectives on the possible 
link between iron excess and atherosclerotic and 
cardiovascular disorders and raised questions about 
the mechanism of parenchymal iron loading in the 
presence of normal transferrin saturation.
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